
Currently out of the existing stock ratings of Mark Breidenbach, 180 are a BUY (97.3%), 5 are a HOLD (2.7%).
Analyst Mark Breidenbach, has had 35.44% of price targets met with an average potential upside of 48.94%, reached in 203 days on average. Previously, Mark Breidenbach worked at OPPENHEIMER, ROTH MKM, HC WAINWRIGHT.
Mark Breidenbach has documented 343 price targets and ratings displayed on 30 stocks. The coverage was on Healthcare, Industrials, Technology, Consumer Cyclical sectors.
Most recent stock forecast was given on BLUE, Bluebird bio at 15-Aug-2024.
Analyst best performing recommendations are on KDMN (KADMON HOLDINGS).
The best stock recommendation documented was for ARVN (ARVINAS) on 12/14/2020. The price target of $80 was fulfilled within 8 days with a profit of $21.62 (37.03%), with a performance score of 46.29.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 17-Aug-2026
$6
$4.96 (476.92%)
$5
3 months 2 days ago
(17-Aug-2026)
1/10 (10%)
$3.92 (188.46%)
148
Buy Since 15-Apr-2026
$10
$8.5 (566.67%)
$10
6 months 28 days ago
(22-Apr-2026)
0/2 (0%)
$7.61 (318.41%)
Sell Since 16-Apr-2026
7 months 3 days ago
(16-Apr-2026)
0/3 (0%)
$2.86 (55.64%)
Buy Since 04-Apr-2023
$11
$9.96 (957.69%)
$12
7 months 3 days ago
(16-Apr-2026)
0/12 (0%)
$8.63 (364.14%)
Hold Since 21-Mar-2023
$3.85
$2.81 (270.19%)
$6
7 months 5 days ago
(14-Apr-2026)
1/2 (50%)
$1.57 (68.86%)
44